Nova Leap Health Corp (NLH) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Nova Leap Health Corp stock C$0.60, price C$0.50, upside +20.0%, quality 61 out of 100. Rating: undervalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
60‑month range C$0.1250 – C$0.8200 · fair‑value band C$0.3500 – C$0.9800 · the C$0.5000 price screens below the C$0.6000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.
Follow Nova Leap Health in your weekly email
Every Wednesday you see whether Nova Leap Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Nova Leap Health Corp., together with its subsidiaries, provides home-based and community-based healthcare services in the United States and Canada.
Show moreShow less
It offers home and home health care services, including dementia care, companionship, personal and skilled nursing care, respite care, palliative care, care management, cooking and meal preparation, light housekeeping, daily living activities, transportation, medication reminders, and medication administration by nursing staff.
The company provides its services through private homes, assisted living communities, hospitals, nursing homes, hospice, and rehabilitation centers. Nova Leap Health Corp. was incorporated in 2015 and is headquartered in Halifax, Canada.
Stock analysis
Nova Leap Health Corp (NLH) currently trades at C$0.5000, while our model-based Fair Value estimate is C$0.6000, implying the stock looks roughly 17% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of C$0.6000 per share, and 4 of the 13 models we run sit above the C$0.5000 price.
Bear case: the Earnings-Based group reads lowest at C$0.1700, and 9 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: C$0.3500 (bear) to C$0.9800 (bull), the price of C$0.5000 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Nova Leap Health Corp reported revenue of $31.5M in FY2025 versus $21.3M in FY2021, a compound +10.3%/yr. Reported net income was −$190K in FY2025.
Key figures
Market cap C$43.7M (≈ $30.6M) Micro · P/S ratio 1.00 · Net margin 0.7% · Return on equity 1.1% · Return on assets (EBIT) 4.1% (5-year average) · Operating margin 3.7% · Revenue (TTM) $32.2M · Revenue growth (YoY) +10.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 82% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 20%, NLH screens cheaper than that median.
Fair Value models
BearC$0.3500Fair Value C$0.6000BullC$0.9800
Price C$0.5000 · Upside +20.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.73/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+22.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+134.6%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
10.5% (2020) → 3.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +10.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside+20.0% · Above median
Profitability
Return on equity (12 months)1.1% · Below median
Return on assets−0.8% · Bottom 25%
Net margin (12 months)0.7% · Bottom 25%
Operating margin (12 months)3.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)10.7% · Above median
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/B1.61× · Cheaper than median
P/S (12 months)0.95× · Cheaper than median
Price / free cash flow (fiscal year)19.7× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Nova Leap Health Corp Fair Value". https://www.fairvalue-calculator.com/stock/NLH
Frequently asked questions
Is Nova Leap Health Corp (NLH) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of C$0.6000 versus a price of C$0.5000, about +20% upside (undervalued).
What is the fair value of NLH?
Our model-based fair value for Nova Leap Health Corp is C$0.6000 (as of Nov 12, 2026), built from audited fundamentals. The current price: C$0.5000.
What is the quality score of NLH?
Nova Leap Health Corp has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nova Leap Health Corp (NLH)?
Our model-based price target is the fair value of C$0.6000 (as of Nov 12, 2026) from 13 valuation models. Cautious scenario C$0.3500, optimistic scenario C$0.9800. It is a calculation from audited fundamentals, not an analyst target.
What is the Nova Leap Health Corp stock forecast for 2026?
Our models put fair value at C$0.6000, about +20% upside versus a price of C$0.5000 (undervalued). Cautious scenario C$0.3500, optimistic scenario C$0.9800. The calculation is refreshed regularly with new filings.
What is the revenue of Nova Leap Health Corp (NLH)?
Nova Leap Health Corp reported trailing-twelve-month revenue of about $32.2M (latest available figure, as of Nov 12, 2026).
What growth is priced into Nova Leap Health Corp (NLH)?
For today's price to be fair in a discounted-cash-flow model, Nova Leap Health Corp would have to grow free cash flow by +12.8 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.7 % per year. As of Nov 12, 2026.
What discount rate (WACC) does the fair value of NLH use?
Our models discount Nova Leap Health Corp at 11.0 %: a base by market capitalisation (nano), damped by beta 1.61, country premium for Canada. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Nova Leap Health Corp that is +12.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Nova Leap Health Corp (NLH) delivered so far?
Over the past 5 years revenue at Nova Leap Health Corp grew +12.7 % a year. The price currently implies free-cash-flow growth of +12.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Nova Leap Health Corp (NLH) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Nova Leap Health Corp (+12.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Nova Leap Health Corp (NLH)?
The free-cash-flow yield on the price is 5.08 %: that much free cash flow Nova Leap Health Corp produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Nova Leap Health Corp (NLH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nova Leap Health Corp it is C$0.6000 per share (as of Nov 12, 2026), against a price of C$0.5000. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Nova Leap Health Corp stock overvalued or undervalued in 2026?
As of Nov 12, 2026, NLH trades below its calculated fair value: price C$0.5000, fair value C$0.6000, a gap of about +20% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NLH?
No. The price is what the market pays today (C$0.5000); the fair value is what the company's own numbers justify (C$0.6000). For Nova Leap Health Corp the two are C$0.1000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nova Leap Health Corp worth?
The market values Nova Leap Health Corp at about C$43.7M (market capitalisation, as of Nov 12, 2026). Per share that is C$0.5000; our models calculate a fair value of C$0.6000 per share.
What do the bullish and bearish scenarios say about NLH?
Our models span a range for Nova Leap Health Corp: cautious scenario C$0.3500, base C$0.6000, optimistic C$0.9800 per share (as of Nov 12, 2026, price C$0.5000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nova Leap Health Corp (NLH)?
Balance-sheet figures for Nova Leap Health Corp (as of Nov 12, 2026): return on equity 1.1%, debt of 0.01 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is NLH from its 52-week high?
Nova Leap Health Corp trades at C$0.5000, about 15% below its 52-week high of C$0.5900 and 82% above the low of C$0.2750 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.6000 is for.
Which stocks are comparable to Nova Leap Health Corp?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nova Leap Health Corp stock attractive at the current price?
The data as of Nov 12, 2026: price C$0.5000, calculated fair value C$0.6000 (+20%), Quality Score 61/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NLH calculated?
We run Nova Leap Health Corp through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of C$0.6000 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Nova Leap Health Corp currently trades 17% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nova Leap Health Corp (NLH)?
The closing price on Nov 11, 2026 was C$0.5000. Our model-based fair value is C$0.6000, about +20% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nova Leap Health Corp right now?
The model range is unusually wide (C$0.3500 to C$0.9800). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Nova Leap Health Corp
How large is the market capitalisation of Nova Leap Health Corp (NLH)?
The market capitalisation of Nova Leap Health Corp is C$43.7M (≈ $30.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nova Leap Health Corp (NLH)?
The price-to-sales ratio of Nova Leap Health Corp is 1.00 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Nova Leap Health Corp (NLH)?
The net margin of Nova Leap Health Corp is 0.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nova Leap Health Corp (NLH)?
The return on equity (ROE) of Nova Leap Health Corp is 1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nova Leap Health Corp (NLH)?
On an EBIT basis the return on assets of Nova Leap Health Corp is 4.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nova Leap Health Corp (NLH)?
The operating margin of Nova Leap Health Corp is 3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nova Leap Health Corp (NLH)?
Revenue at Nova Leap Health Corp is growing +10.7% versus a year earlier (3y avg +3.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nova Leap Health Corp (NLH)?
Earnings per share at Nova Leap Health Corp are growing −41.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Nova Leap Health Corp (NLH) carry?
The net debt of Nova Leap Health Corp is $514K (fiscal year 2025, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Nova Leap Health Corp in the live analysis
One click puts Nova Leap Health Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 12, 2026